Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELSPIRE: Elafibranor in Primary Biliary Cholangitis
NCT06383403Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of elafibranor in primary biliary cholangitis (PBC), sponsored by Ipsen. Started Jul 2024; status: completed.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06383403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383403.